Al-Ola Abdallah, Associate Professor at the University of Kansas Medical Center, shared on X:
“Ramantamig: Deep Responses, Durable Control and Outpatient Potential Updated phase I TRILogy – 1 findings in triple – class exposed relapsed refractory multiple myeloma are encouraging.
Among 47 BCMA GPRC5D – naïve patients treated at the recommended phase II dose:
- 93.6% overall response rate
- 78.7% achieved complete response or better
- MRD negativity: 95% at 10⁻⁵ (19/20) and 93.3% at 10⁻⁶ (14/15) among evaluable patients
- Estimated 24-month PFS: 81.3%, with median follow-up of 21.8 months
- Median duration of response not reached
Subcutaneous dosing every 4 weeks, with an option to extend to 8 weeks.
In the dedicated outpatient cohort (n=30), 93.3% completed step – up dosing and 79.3% completed the first treatment dose as outpatients. With prophylactic tocilizumab used in 96.6%, CRS occurred in 10% at step-up dosing and 6.7% at the first treatment dose – all grade 1.”
Other articles featuring Al-Ola Abdallah on OncoDaily.
